ArticleBritish journal of cancer1995
Insulin-like growth factors: the unrecognised oncogenes.
Article in British journal of cancer, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.Oncotarget · 2016Article
- Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway.Molecular cancer · 2016Article
- A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.International journal of endocrinology · 2013Article
- Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- The coexistence of an intrasellar adenoma, lymphocytic hypophysitis, and primary pituitary lymphoma in a patient with acromegaly.Case reports in endocrinology · 2011Article
- Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.Expert review of molecular diagnostics · 2010Review
- Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines.British journal of cancer · 2008Article
- Autoantibodies to tumor-associated antigens: reporters from the immune system.Immunological reviews · 2008Review
- Energy balance, insulin resistance biomarkers, and breast cancer risk.Cancer detection and prevention · 2007Article
- Article
- Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.Clinical and experimental immunology · 2003Review
- Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.The Journal of clinical investigation · 2001Article
- CTGF (IGFBP-rP2) is specifically expressed in malignant lymphoblasts of patients with acute lymphoblastic leukaemia (ALL).British journal of cancer · 2000Article
- Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.British journal of cancer · 2000Article
- Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Toward checkmate: biology and breast cancer therapy for the new millennium.Investigational new drugs · 1999Review
- Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.